HALO - Halozyme Therapeutics Non-GAAP EPS of $0.53 revenue of $152.37M; raises FY22 outlook
- Halozyme Therapeutics press release ( NASDAQ: HALO ): Q2 Non-GAAP EPS of $0.53.
- Revenue of $152.37M.
- Financial Outlook for 2022
- The Company is raising its financial guidance for 2022 which was last provided on May 10, 2022, as a result of the recent close of the Antares Pharma transaction and strong year-to-date results.
- Total revenue of $655 million to $685 million, an increase from its prior guidance range of $530 million to $560 million, representing growth of 48% to 55% over 2021 total revenue primarily driven by projected revenue contribution from the Antares business of $115 million to $125 million.
- Consensus Revenue Estimate for 2022 is $685.14M.
- Non-GAAP diluted earnings per share are expected to be $2.10 to $2.25, an increase from its prior guidance range of $2.05 to $2.20, reflective of the projected accretion from the Antares Pharma acquisition.
For further details see:
Halozyme Therapeutics Non-GAAP EPS of $0.53, revenue of $152.37M; raises FY22 outlook